Indian Pharma Set to Capture $10 Billion Off-Patent Market

The global pharmaceutical market is on the brink of a major transformation as a wave of blockbuster drugs lose their patent protection. This "patent cliff" is creating a massive opportunity for generic drug manufacturers, particularly in India, to enter the market with more affordable versions of these high-revenue medications.
The Patent Cliff and Its Implications
As patents on key blockbuster drugs expire, the global pharmaceutical market is poised to undergo significant changes. This 'patent cliff' will allow generic and biosimilar manufacturers, particularly in India, to produce and market cheaper versions of high-revenue drugs, previously dominated by their patented counterparts. The Indian pharmaceutical sector, renowned for its robust generic drug industry, stands to gain substantially from this shift.
Opportunities for Indian Pharma
With its established prowess in generic drug manufacturing, the Indian pharma industry can significantly benefit from the patent cliff. However, tapping into the biosimilar market represents a higher-margin opportunity yet requires overcoming substantial technical and regulatory challenges.